Literature DB >> 9754176

Long-term survival in choroidal and ciliary body melanoma after enucleation versus plaque radiation therapy.

J J Augsburger1, Z M Corrêa, J Freire, L W Brady.   

Abstract

OBJECTIVE: This study aimed to determine whether the long-term melanoma-specific mortality rate of patients with a primary choroidal or ciliary body melanoma treated by enucleation is appreciably lower than that of similar patients treated by plaque radiation therapy.
DESIGN: Retrospective, nonrandomized, comparative clinical trial. PARTICIPANTS: A previously reported group of 237 patients, 140 treated by enucleation and 97 treated by cobalt-60 (Co-60) plaque between May 1976 and June 1980, and a residual group of 122 patients, 51 treated by enucleation and 71 treated by Co-60 plaque, were identified by variable-by-variable range matching. INTERVENTION: Primary treatment by enucleation or Co-60 plaque radiation therapy was performed. MAIN OUTCOME MEASURES: Melanoma-specific mortality and duration of post-treatment survival were measured.
RESULTS: The melanoma-specific mortality rate was substantially worse in the original enucleation subgroup over the entire 15-year follow-up interval; however, differences in baseline prognostic factors between the subgroups are likely to explain the difference in survival curves. After elimination of patients with nonoverlapping values of individual clinical variables to adjust for recognized intergroup differences at baseline, there was no significant or clinically important difference in the 15-year mortality curves of the residual subgroups. The relative rate ratio for the treatment effect in the residual patients was 0.97 (95% confidence interval, 0.51-1.86). There was no late downturn in the survival curve of the plaque-treated patients or late crossing of the curves.
CONCLUSION: A large difference in survival between equivalent groups of patients with primary choroidal or ciliary body melanoma treated by enucleation versus plaque radiation therapy appears to be unlikely.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9754176     DOI: 10.1016/S0161-6420(98)99037-6

Source DB:  PubMed          Journal:  Ophthalmology        ISSN: 0161-6420            Impact factor:   12.079


  6 in total

1.  Episcleral brachytherapy for uveal melanoma: analysis of 136 cases.

Authors:  Ciro García-Álvarez; María Antonia Saornil; Francisco López-Lara; Ana Almaraz; María Fe Muñoz; Jesús Frutos-Baraja; Yerena Muiños
Journal:  Clin Transl Oncol       Date:  2012-05       Impact factor: 3.405

2.  Long-term risk of local failure after proton therapy for choroidal/ciliary body melanoma.

Authors:  Evangelos S Gragoudas; Anne Marie Lane; John Munzenrider; Kathleen M Egan; Wenjun Li
Journal:  Trans Am Ophthalmol Soc       Date:  2002

3.  Bevacizumab and intraocular tumors: an intriguing paradox.

Authors:  Mariam el Filali; Long V Ly; Gregorius P M Luyten; Mieke Versluis; Hans E Grossniklaus; Pieter A van der Velden; Martine J Jager
Journal:  Mol Vis       Date:  2012-10-05       Impact factor: 2.367

4.  Long-term followup comparing two treatment dosing strategies of (125) I plaque radiotherapy in the management of small/medium posterior uveal melanoma.

Authors:  Timothy G Murray; Arnold M Markoe; Aaron S Gold; Fiona Ehlies; Ernesto Bermudez; Andrea Wildner; Azeema Latiff
Journal:  J Ophthalmol       Date:  2013-02-28       Impact factor: 1.909

5.  Triamcinolone acetonide and anecortave acetate do not stimulate uveal melanoma cell growth.

Authors:  Mariam El Filali; Irene Homminga; Willem Maat; Pieter A van der Velden; Martine J Jager
Journal:  Mol Vis       Date:  2008-09-24       Impact factor: 2.367

6.  Atypical Presentation: Metastatic Uveal Melanoma in a Young Patient without Visual Complaints.

Authors:  Pedro Grachinski Buiar; Sérgio Jobim de Azevedo
Journal:  Front Oncol       Date:  2017-05-18       Impact factor: 6.244

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.